Phase 2 (Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: PN-943 (α4β7-Integrin Antagonist) for Ulcerative Colitis (UC) - Phase 2 Data
ClinicalTrials.gov (NCT04504383): PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
WHAT IS THE CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the treatment of inflammatory bowel disease. PN-943 is designed to offer the convenience of oral administration and the potential for improved safety and tolerability compared to antibody therapeutics administered by injection that target the alpha-4-beta-7 integrin pathway. PTG-100, a PN-943 analog, showed evidence of clinical and histological remission in patients with ulcerative colitis. PN-943 has completed Phase 1 development, demonstrating sustained target engagement with two weeks of daily administration.
In 2015, an estimated 1.3% of US adults (3 million) reported being diagnosed with IBD (either Crohn’s disease or ulcerative colitis). This was a large increase from 1999 (0.9% or 2 million adults).
Learn more at CDC.gov
Updated by HC
PRTK, Ulcerative Colitis (UC), inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in your digestive tract, PN-943 (α4β7-Integrin Antagonist)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post